IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus

IFP35 作为一种有前景的生物标志物和治疗靶点,可用于研究 SARS-CoV-2 或流感病毒引起的综合征。

阅读:1
作者:Yang Yu ,Na Xu ,Qi Cheng ,Fei Deng ,Meiqin Liu ,Airu Zhu ,Yuan-Qin Min ,Dan Zhu ,Wenbo Huang ,Xu Feng ,Xizhong Jing ,Ying Chen ,Daoyuan Yue ,Yawei Fan ,Chang Shu ,Qing Guan ,Zifeng Yang ,Jincun Zhao ,Wenjun Song ,Deyin Guo ,Huanliang Liu ,Jindong Zhao ,Ping Lan ,Zhengli Shi ,Yingfang Liu ,Xiaoping Chen ,Huanhuan Liang

Abstract

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key factors participating in the cytokine storm. Here we demonstrate that interferon-induced protein 35 (IFP35) plays an important role in the cytokine storm induced by SARS-CoV-2 and influenza virus infection. We find that the levels of serum IFP35 in individuals with SARS-CoV-2 correlates with severity of the syndrome. Using mouse model and cell assays, we show that IFP35 is released by lung epithelial cells and macrophages after SARS-CoV-2 or influenza virus infection. In addition, we show that administration of neutralizing antibodies against IFP35 considerably reduces lung injury and, thus, the mortality rate of mice exposed to viral infection. Our findings suggest that IFP35 serves as a biomarker and as a therapeutic target in virus-induced syndromes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。